Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

39.72USD
3:40pm EDT
Change (% chg)

$-0.11 (-0.28%)
Prev Close
$39.83
Open
$39.75
Day's High
$39.99
Day's Low
$39.43
Volume
3,213,360
Avg. Vol
5,629,787
52-wk High
$50.40
52-wk Low
$33.60

MYL.O

Chart for MYL.O

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $21,348.15
Shares Outstanding(Mil.): 535.98
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 39.69 14.31 17.43
EPS (TTM): 1.00 -- --
ROI: 2.20 -7.26 -5.41
ROE: 4.86 -6.76 -4.69

BRIEF-Mylan NV says CEO's 2016 compensation was $13.8 mln

* Mylan NV says CEO Heather Bresch's 2016 total compensation $13.8 million - sec filing

May 23 2017

Mylan disagrees with FDA over generic Advair delay

Generic drug maker Mylan NV on Wednesday said it disagrees with the reasoning behind the U.S. Food and Drug Administration's decision not to approve its generic for GlaxoSmithKline Plc's blockbuster Advair in March. | Video

May 10 2017

UPDATE 4-Mylan disagrees with FDA over generic Advair delay

* Shares fall in afternoon trading (Adds analyst comment, updates shares)

May 10 2017

Mylan says disagrees with FDA over generic Advair delay

NEW YORK Drugmaker Mylan Inc , which is trying to launch a generic form of GlaxoSmithKline's Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the standards it must meet.

May 10 2017

BRIEF-Mylan says EpiPen sales suffer from increased competition

* President says EpiPen will account for less than 5 percent of global revenue and less than 10 percent of north american sales

May 10 2017

Mylan says disagrees with FDA over generic Advair delay

NEW YORK, May 10 Drugmaker Mylan Inc, which is trying to launch a generic form of GlaxoSmithKline's Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the standards it must meet.

May 10 2017

EpiPen maker Mylan's profit surges

May 10 EpiPen maker Mylan NV said on Wednesday first-quarter profit more than quadrupled, as the maker of generic drugs benefited from strong demand outside the United States.

May 10 2017

BRIEF-Mylan CEO Heather Bresch's 2016 total compensation $13.8 mln

* CEO Heather Bresch's 2016 total compensation $13.8 million versus $18.9 million in 2015 - SEC filing Source: (http://bit.ly/2pBt59h) Further company coverage:

May 01 2017

BRIEF-Mylan nominates Sjoerd Vollebregt for election to board

* Mylan nv - nominated sjoerd s. Vollebregt as a candidate for election to mylan's board at 2017 annual meeting of shareholders

May 01 2017

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

France's Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Apr 24 2017

More From Around the Web

Earnings vs. Estimates